Alhalabi OT, Göttmann M, Gold MP, Schlue S, Hielscher T, Iskar M, Kessler T, Hai L, Lokumcu T, Cousins CC, Herold-Mende C, Heßling B, Horschitz S, Jabali A, Koch P, Baumgärtner U, Day BW, Wick W, Sahm F, Krieg SM, Fraenkel E, Phillips E, Goidts V. Integration of transcriptomics, proteomics and loss-of-function screening reveals WEE1 as a target for combination with dasatinib against proneural glioblastoma. Cancer Lett. 2024 605:217265.
Fazio L, Naik VN, Therpurakal RN, Gomez Osorio FM, Rychlik N, Ladewig J, Strüber M, Cerina M, Meuth SG, Budde T. Retigabine, a potassium channel opener, restores thalamocortical neuron functionality in a murine model of autoimmune encephalomyelitis. Brain Behav Immun. 2024 122:202-215.
Hai L, Hoffmann DC, Wagener RJ, Azoŕin DD, Hausmann D, Xie R, Huppertz MC, Hiblot J, Sievers P, Heuer S, Ito J, Cebulla G, Kourtesakis A, Kaulen LD, Ratliff M, Mandelbaum H, Jung E, Jabali A, Horschitz S, Ernst KJ, Reibold D, Warnken U, Venkataramani V, Will R, Suvà ML, Herold-Mende C, Sahm F, Winkler F, Schlesner M, Wick W, Kessler T. A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1. Nat Commun. 2024 15(1):968.
Zaidi D, Chinnappa K, Yigit BN, Viola V, Cifuentes-Diaz C, Jabali A, Uzquiano A, Lemesre E, Perez F, Ladewig J, Ferent J, Ozlu N, Francis F. Forebrain Eml1 depletion reveals early centrosomal dysfunction causing subcortical heterotopia. J Cell Biol. 2024 223(12)